Business Context and Reporting Period
This Form 6-K filing by YD Bio Limited covers the month of January 2026. The report discloses the entry into a binding Letter of Intent (LOI) on January 20, 2026, to acquire SafeSave Medical Cell Sciences & Technology Co., Ltd. (SSMC). The transaction involves the acquisition of 100% of SSMC's equity interests indirectly through a newly formed offshore holding company, Safe Save Cell (KY) Holdings Limited.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity metrics for YD Bio Limited. The primary financial data disclosed relates to the proposed transaction:
- Total Consideration: Expected to be NT$839,832,000.
- Payment Structure: A mix of cash and YD Bio ordinary shares.
- Shareholder Allocation: Specific shareholders holding more than 10% (including the founder) will receive shares via swap; general shareholders may choose cash or shares.
Material Changes
The material change reported is the initiation of the acquisition process for SSMC. This represents a strategic expansion into SSMC's business and assets. The filing notes that SSMC will undergo a corporate restructuring to establish the KY Company prior to the acquisition. No other material changes to the Company's existing operations or financial condition are detailed in this specific report.
Guidance, Outlook, and Risks
Timeline and Conditions:
- Due Diligence Target: Completion expected by March 20, 2026.
- Closing Target: Expected within 30 days following due diligence.
- Conditions Precedent: Includes completion of due diligence, SSMC restructuring, and the absence of material adverse changes in SSMC's business or financial condition.
- General shareholders: Six-month transfer restriction.
- Specific shareholders: One-year transfer restriction.
- There is no assurance that definitive agreements will be signed or that the transaction will close on the anticipated terms or timeline.
- The LOI is expected to be superseded by a definitive agreement.
- Forward-looking statements are subject to significant uncertainties and assumptions beyond the Company's control.
Investor Verification Checklist
- Verify the final terms of the definitive agreement once signed, as the LOI is non-binding regarding the final transaction structure.
- Confirm the exact split between cash and equity consideration in the final deal.
- Monitor the completion of SSMC's corporate restructuring and the due diligence process by the March 20, 2026 target date.
- Review the impact of the share issuance on existing shareholder dilution once the share count is finalized.
- Assess the financial health and business viability of SSMC during the due diligence period.